The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.

Kyowa Kirin announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody, after a safety review identified “emerging concerns” of ...

Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases. | Two new cancer cases have ...

A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug ...

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in ...

March 3 (Reuters) - Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions after the company concluded that the potential risks may ...

Japanese drugmaker Kyowa Kirin has discontinued all clinical trials of rocatinlimab after new malignancy concerns emerged in the program, abruptly ending development of the anti-OX40 antibody across ...

Kirin Holdings has agreed to sell Kentucky-based bourbon whiskey unit Four Roses Distillery to E. & J. Gallo Winery in a $775 million deal. The Japanese beer and beverage maker said Friday that it ...

Created with American consumers in mind, the new flavors bring Hyoketsu’s signature crisp, fruit-forward taste to two key U.S. markets.

Wine giant Gallo says it plans to add a prominent Kentucky bourbon brand to its portfolio in a deal to purchase Four Roses Distillery from Japanese-based Kirin.